Androgen deprivation therapy combined with postoperative radiotherapy for prostate cancer management
- PMID: 38763152
- DOI: 10.1016/S0140-6736(24)00802-X
Androgen deprivation therapy combined with postoperative radiotherapy for prostate cancer management
Conflict of interest statement
AP declares funding from the National Institutes of Health and National Cancer Institute, a Varian/Siemens research grant as co-investigator, participation in the NRG Oncology Translational Research Program (Chair Emeritus), and leadership roles at the University of Miami (related to Department Chair). ADP declares research support from Veracyte (to trial sponsor), participation on advisory boards for Pfizer and Merck, and a leadership role at the University of Miami (Medical Director).
Comment on
-
Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial.Lancet. 2024 Jun 1;403(10442):2416-2425. doi: 10.1016/S0140-6736(24)00549-X. Epub 2024 May 16. Lancet. 2024. PMID: 38763153 Free PMC article. Clinical Trial.
-
Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial.Lancet. 2024 Jun 1;403(10442):2405-2415. doi: 10.1016/S0140-6736(24)00548-8. Epub 2024 May 16. Lancet. 2024. PMID: 38763154 Free PMC article. Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
